Physician profile
Steven Campbell
NPI 1861768988
$5,417.19
in general payments reported to CMS, 2019-2025
33 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $637 · 2021: $703 · 2022: $523 · 2023: $874 · 2024: $788 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707 · Consulting Fee: $200 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.95 |
| Consulting Fee | $200.00 |
| Education | $198.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $802.78 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Glaxosmithkline, LLC. | $713.54 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $623.48 | 2019-2025 | Breztri, Symbicort, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.55 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $410.09 | 2019-2024 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $330.26 | 2019-2023 | |
| Genzyme Corporation | $193.38 | 2021-2025 | |
| Grifols USA, LLC | $181.59 | 2019-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $175.20 | 2022-2024 | Yupelri |
| Genentech USA, INC. | $153.56 | 2020-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $133.35 | 2021-2025 | Glassia |
| Covidien LP | $122.78 | 2019 | |
| Mallinckrodt Hospital Products INC. | $118.06 | 2020-2023 | Acthar |
| Regeneron Healthcare Solutions, INC. | $102.92 | 2022-2024 | Dupixent |
| United Therapeutics Corporation | $102.34 | 2021-2024 | Tyvaso |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Mallinckrodt Enterprises LLC | $96.39 | 2019 | |
| Merck Sharp & Dohme LLC | $84.55 | 2023-2025 | Winrevair |
| Sunovion Pharmaceuticals INC. | $84.18 | 2019-2021 | |
| Vifor Pharma, INC. | $64.25 | 2024-2025 | Zemaira |
| Pulmonx Corporation | $49.84 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Baxter Healthcare | $27.05 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Harmony Biosciences LLC | $26.95 | 2024 | |
| Paratek Pharmaceuticals, INC. | $26.80 | 2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $23.36 | 2023 | |
| Jazz Pharmaceuticals INC. | $21.42 | 2025 | |
| Inogen, INC. | $20.84 | 2024 | |
| Advanced Respiratory, INC | $19.48 | 2021 | |
| Pfizer INC. | $15.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.52 | 2020 | |
| Abbvie INC. | $12.72 | 2019 | |
| Gilead Sciences, INC. | $11.82 | 2021 | |
| Fisher & Paykel Healthcare INC | $10.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.